Search: id:"swepub:oai:DiVA.org:oru-97588" >
2021 European guide...
-
Jensen, J. S.Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark
(author)
2021 European guideline on the management of Mycoplasma genitalium infections
- Article/chapterEnglish2022
Publisher, publication year, extent ...
-
2022-02-19
-
Wiley-Blackwell Publishing Inc.2022
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:oru-97588
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-97588URI
-
https://doi.org/10.1111/jdv.17972DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Mycoplasma genitalium infection contributes to 10-35% of non-chlamydial non-gonococcal urethritis in men. In women, M. genitalium is associated with cervicitis and pelvic inflammatory disease (PID) in 10-25%. Transmission of M. genitalium occurs through direct mucosal contact.CLINICAL FEATURES AND DIAGNOSTIC TESTS: Asymptomatic infections are frequent. In men, urethritis, dysuria and discharge predominate. In women, symptoms include vaginal discharge, dysuria or symptoms of PID - abdominal pain and dyspareunia. Symptoms are the main indication for diagnostic testing. Diagnosis is achievable only through nucleic acid amplification testing and must include investigation for macrolide resistance mutations.THERAPY: Therapy for M .genitalium is indicated if M. genitalium is detected. Doxycycline has a cure rate of 30-40%, but resistance is not increasing. Azithromycin has a cure rate of 85-95% in macrolide-susceptible infections. An extended course of azithromycin appears to have a higher cure rate, and pre-treatment with doxycycline may decrease organism load and the risk of macrolide resistance selection. Moxifloxacin can be used as second-line therapy but resistance is increasing.RECOMMENDED TREATMENT: Uncomplicated M. genitalium infection without macrolide resistance mutations or resistance testing: Azithromycin 500 mg on day one, then 250 mg on days 2-5 (oral). Second-line treatment and treatment for uncomplicated macrolide-resistant M. genitalium infection: Moxifloxacin 400 mg od for 7 days (oral). Third-line treatment for persistent M. genitalium infection after azithromycin and moxifloxacin: Doxycycline or minocycline 100 mg bid for 14 days (oral) may cure 40-70%. Pristinamycin 1 g qid for 10 days (oral) has a cure rate of around 75%. Complicated M. genitalium infection (PID, epididymitis): Moxifloxacin 400 mg od for 14 days. MAIN CHANGES FROM THE 2016 EUROPEAN M.GENITALIUM GUIDELINE: Due to increasing antimicrobial resistance and warnings against moxifloxacin use, indications for testing and treatment have been narrowed to primarily involve symptomatic patients. The importance of macrolide resistance-guided therapy is emphasised.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Cusini, M.Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
(author)
-
Gomberg, M.Moscow Scientific and Practical Centre of Dermatovenereology and Cosmetology, Moscow, Russia
(author)
-
Moi, H.Olafia Clinic, Oslo University Hospital, Institute of Medicine, University of Oslo, Oslo, Norway
(author)
-
Wilson, J.Genitourinary Medicine and HIV, Leeds Teaching Hospitals NHS Trust, Leeds, UK
(author)
-
Unemo, Magnus,1970-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,WHO Collaborating Centre for Gonorrhoea and other STIs, Department of Laboratory Medicine(Swepub:oru)muo
(author)
-
Microbiology and Infection Control, Statens Serum Institut, Copenhagen, DenmarkFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
(creator_code:org_t)
Related titles
-
In:Journal of the European Academy of Dermatology and Venereology: Wiley-Blackwell Publishing Inc.36:5, s. 641-6500926-99591468-3083
Internet link
Find in a library
To the university's database